Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience

Foubert, Fanny; Salimon, Maëva; Dumars, Clotilde; Régenet, Nicolas; Girot, Paul; Venara, Aurélien; Senellart, Hélène; Heymann, Marie-Françoise; Matysiak‐Budnik, Tamara; Touchefeu, Yann

doi:10.21037/jgo.2018.09.13

Cited by 4 publications

(3 citation statements)

References 35 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other significant prognostic markers incorporated into the GI-NEC score were LDH, PS, alkaline phosphatase (ALP) and presence of liver metastases [14]. A further retrospective study of 151 patients with intestinal and pancreatic NENs (70% of whom were grade 3), identified age at diagnosis >65 years, presence of metastases, higher grade and large primary tumour size as adverse prognostic markers [15].…”

Section: Introductionmentioning

confidence: 99%

Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia

Abdelmalak

Lythgoe

Evans

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: High-grade neuroendocrine tumours and carcinomas (NET/NECs) behave aggressively, typically presenting at an advanced stage. Prognosis is poor, with median survival between 5 and 34 months. The mainstay of treatment is palliative systemic therapy. However, therapy carries a risk of toxicity, which can reduce quality of life. Therefore, accurate prognostic scores for risk stratification of patients with high-grade NET/NECs are needed to help guide patient management to decide whether active treatment is likely to improve overall survival (OS). We aimed to compare the prognostic ability of published prognostic scores to predict OS in a cohort of patients with high-grade NET/NECs of any primary site. Methods: Treatment, biochemical and clinicopathological data were collected retrospectively from 77 patients with high-grade NET/NECs across three hospitals between 2016 and 2020. Variables including performance status (PS), Ki-67, age at diagnosis, previous treatment and presence of liver metastases were recorded. Pre-treatment neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio, modified Glasgow prognostic score (mGPS), and gastrointestinal neuroendocrine carcinoma (GI-NEC) score were derived. Univariable and multivariable survival analyses were used to assess prognostic ability. Results: The median age of the cohort was 63 years (range: 31–85); 53% of subjects were female. Grade 3 NETs (G3-NETs) were identified in 32 patients and NECs in 45 patients. The median OS was 13.45 months (range: 0.87–65.37) with no difference observed between G3-NETs and NECs. Univariable analysis revealed that NLR (n = 72, p = 0.049), mGPS (n = 56, p = 0.003), GI-NEC score (n = 27, p = 0.0007) and Ki-67 (n = 66, p = 0.007) were significantly associated with OS. Multivariable analysis confirmed that elevated mGPS (p = 0.046), GI-NEC score (p = 0.036), and Ki-67 (p = 0.02) were independently prognostic for reduced OS across the entire cohort. mGPS was identified as an independent prognostic factor in G3-NETs. Independent predictors of OS in NECs were PS and Ki-67. Conclusions: mGPS, PS and Ki-67 are independent prognostic markers in high-grade NET/NEC patients. Our study supports the use of these prognostic scores for risk stratification of patients with high grade cancers and as useful tools to guide treatment decisions.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia

Abdelmalak

Lythgoe

Evans

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The clinicopathological characteristics of G-NEN are different in patients over the world. A number of studies have generally grouped all neuroendocrine tumors of the digestive system into one [3][4][5], but studies focus on G-NEN alone Accounted for very little. Therefore, we retrospectively collected the clinicopathological data and follow-up data of patients with a gastric neuroendocrine tumor in a Chinese hospital in this study, and we conducted a detailed analysis aiming to explore the clinicopathological characteristics of patients with G-NEN and the factors related to survival, which might provide new clues for the research of this sort of tumors.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Features and Prognosis of Gastric Neuroendocrine Neoplasms

Wang

Wen

Tian

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Purpose: We performed a retrospective study to investigate the relationship between clinicopathological features and prognosis of G-NEN.Methods: Clinicopathological features and follow-up data of 67 patients with G-NEN treated at Shandong Provincial Hospital affiliated of Shandong University were analyzed retrospectively. Results: This whole cohort included 53 males and 14 females, with a mean age of 59.37±9.80 years. The clinical symptoms and the primary tumor site were not specific. Neuroendocrine tumor, neuroendocrine carcinoma, and mixed neuroendocrine–non‐neuroendocrine neoplasm accounted for 14.93%, 59.70%, and 25.37%, respectively. TNM stages Ⅰ-Ⅳ: 6, 6, 49, 4, respectively. All patients underwent surgically treated. Forty-five patients underwent laparoscopic surgery, and twenty-two patients received an open approach. The median survival time was 36 months in all patients. The overall survival rate for the entire cohort was 68.1 %, 44.7 %, and 34.5% at 1, 3, and 5 years, respectively. Logistic regression analysis revealed that the invasive depth of tumors was predictors for metastasis. The univariate analysis confirmed that smoking, T stage, distant metastasis, and surgical method were related to survival. COX regression analysis showed that the T stage (HR=4.817, 95%CI: 1.021-22.729, P=0.047) was an independent risk factor for evaluating the prognosis of patients with G-NEN.Conclusions: G-NEN is a kind of rare tumors that can occur at any part of the stomach. The clinical features are not specific. The tumor invasive depth related to tumor metastasis. The prognosis is associated with smoking, T stage, distant metastasis, and surgical method. Of them, T stage is an independent prognostic factor for G-NEN patients. But larger studies are needed in the future.

show abstract

“…Different response rates and survival outcomes of NETs, even within the same group, might be attributed to its heterogeneous nature. There are number of studies in the literature to identify prognostic or predictive markers in NETs [7][8][9][10]. However, there are still no well-established…”

mentioning

confidence: 99%

Is There a Novel Prognostic Parameter for Well-Differentiated Neuroendocrine Tumours? The Prognostic Value of Albumin and Hemoglobin in Patients Well-Differentiated Neuroendocrine Tumours

Açıkgöz

Bal

Doğan

2019

CMRO

View full text Add to dashboard Cite

Background: Neuroendocrine tumours (NETs) are a heterogeneous group of tumours. There are no well-established prognostic factors for accurately predicting survival of patients with well-differentiated NETs. Prognostic value of inflammatory markers was evaluated in some solid tumours previously. However, it was not well documented in orphan tumours like well-differentiated NETs. We aimed to find out a novel and easy-accessible prognostic parameter by using hemogram & biochemical parameters in patients with well-differentiated NETs. Patients and Methods: 132 patients with well-differentiated NETs were analyzed, retrospectively. Patients were subgrouped into two groups with respect to the cutoff value that was determined by ROC analysis. Survival analysis was performed by using the Kaplan-Meier method with the Long-rank test. p<0.05 was considered statistically significant. Results: The cutoff value was defined as 47.94 for AlbXHb. High-risk (AlbXHb < 47.94) group had significantly increased risk of death (HR:5.16, 95%CI 1.45-18.38 p=0.011). AlbXHb was a significant prognostic factor for OS in univariate analyses (HR=0.925 95% CI 0.878-0.974, p=0.003). Conclusion: We demonstrated that AlbXHb might be a novel prognostic factor for well-differentiated NETs, but it needs further evaluation by randomized clinical trials. We believe that this novel parameter has feasible accuracy for predicting disease outcomes.

show abstract

Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience

Cited by 4 publications

References 35 publications

Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia

Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia

Clinicopathological Features and Prognosis of Gastric Neuroendocrine Neoplasms

Is There a Novel Prognostic Parameter for Well-Differentiated Neuroendocrine Tumours? The Prognostic Value of Albumin and Hemoglobin in Patients Well-Differentiated Neuroendocrine Tumours

Contact Info

Product

Resources

About